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Much has been learned about the diversity and distribution of human-associatedmicrobial communities, but
we still know little about the biology of the microbiome, how it interacts with the host, and how the host re-
sponds to its resident microbiota. The Integrative Human Microbiome Project (iHMP, http://hmp2.org), the
second phase of the NIH Human Microbiome Project, will study these interactions by analyzing microbiome
and host activities in longitudinal studies of disease-specific cohorts and by creating integrated data sets of
microbiome and host functional properties. These data sets will serve as experimental test beds to evaluate
new models, methods, and analyses on the interactions of host and microbiome. Here we describe the three
models of microbiome-associated human conditions, on the dynamics of preterm birth, inflammatory bowel
disease, and type 2 diabetes, and their underlying hypotheses, as well as the multi-omic data types to be
collected, integrated, and distributed through public repositories as a community resource.Introduction
The human microbiome is important for human health, behavior,
and disease, yet its function and dynamics during healthy and
disease states are onlypartially understood. Studies of themicro-
biome to date have indicated impacts on personalized medicine
ranging from inactivation of pharmaceuticals in some individuals
(Haiser et al., 2013) to increased risk of cardiovascular disease
due tomicrobialmetabolic byproducts (Koeth et al., 2013). These
findings show particular promise given that they have already
come to light early in the field’s transition from high-throughput
discovery to detailedmechanistic studies, a process still ongoing
after more than a decade of human omics. The first phase of the
NIH Human Microbiome Project (HMP, fiscal years 2008–2012,
http://www.commonfund.nih.gov/hmp) examined the diversity
and composition of the human microbiome to evaluate (1) com-
mon patterns of microbial diversity associated with health and
(2) whether taxonomic or functional features of the microbiome
correlated with diseases by analyzing a large healthy cohort
and a set of demonstration projects. These efforts revealed the
vast microbial diversity associated with humans and provided
new insights into the ecology of the host-microbiome supraor-
ganism (HumanMicrobiome Project Consortium, 2012a, 2012b).
Results from previous human microbiome studies (Dethlefsen
et al., 2006; Hooper and Gordon, 2001; Qin et al., 2010; Savage,
1977) and from the first phase of the HMP (Human Microbiome
Project Consortium, 2012a, 2012b) suggested that taxonomic
composition of the microbiomes between subjects can differ
significantly. This indicated that taxonomic characterization alone
may not be sufficient to reveal relationships between the micro-
biome and specific health or disease states. Interestingly, meta-
bolic pathway reconstructions of the metagenomic data from
the HMP healthy cohort study suggested that the microbiomes
of healthy subjects may share similarities in their metabolic
pathways; this feature may be a key common property of the
microbiome within any given cohort (Human Microbiome Project276 Cell Host & Microbe 16, September 10, 2014 ª2014 The AuthorsConsortium, 2012b). Further, in some of the HMP Demonstration
Projects (http://commonfund.nih.gov/hmp/fundedresearch),
analysis of microbiome biological properties, such as community
transcripts, proteins, or metabolites, hinted at losses or gains of
key microbiome functions associated with particular diseases.
The second phase of the HMP (or iHMP, Integrative Human
Microbiome Project Consortium, fiscal years 2013–2016,
http://hmp2.org) will further examine the role of the microbiome
in human health and disease through a study of three models of
microbiome-related human conditions. These three longitudinal
studies focus on (1) pregnancy, including those resulting in pre-
term birth; (2) gut disease onset, using inflammatory bowel dis-
ease (IBD) as a model; and (3) respiratory viral infection and
onset of type 2 diabetes (T2D). In each case, subjects will be fol-
lowed for up to 3 years. Multiple properties of the microbiome,
such as phylogenetic composition and associated functional
omic data (e.g., transcriptome, proteome, metabolites, etc.)
will be analyzed. Importantly, host functional changes will also
be monitored as well as the metabolites originating from both
the host and the microbiome so that microbiome and host
changes can be simultaneously followed to provide a more
comprehensive picture of the dynamic changes that occur dur-
ing these periods. The studies were selected as exemplars of mi-
crobiome-associated human conditions and therefore should be
of broad interest to the research community. These resulting
data sets will provide opportunities for new hypotheses to be
tested and for evaluating the utility of simultaneously assessing
the microbiome and the host biological properties for under-
standing host-microbiome interactions.
Data Deposition, Access, and Sharing
Primary data (e.g., sequence reads or mass spectrometry pro-
files) and derived properties (e.g., microbial composition, gene
expression and protein levels, and metabolite profiles) will be
generated by each project. Table 1 lists the biospecimens and
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mary data. A glossary for the multi-omic properties is included in
Table 2. Primary data will be accessible from public databases
such as SRA (genomic sequences, metagenomic sequences,
transcript data), GEO (gene expression data), EBI PRIDE (prote-
omic data), and the Metabolomics Workbench (http://www.
metabolomicsworkbench.org/, metabolomic data). Protected
data, such as human sequence data and specific clinical meta-
data, will be deposited in the NCBI dbGaP controlled access
database; requests to access these data can be made through
dbGaP (https://dbgap.ncbi.nlm.nih.gov). Bacterial strains will
be deposited in the HMP reference strain collection at ATCC/
BEI. In addition to the public repositories, all nonprotected (i.e.,
nonhuman) data will also be in structured, study-specific data-
bases hosted by each team. In accordance with HMP policies,
all data of sufficiently high quality will be rapidly deposited in pub-
lic repositories in advance of any iHMP Consortium publication.
Analyses will be performed on early data sets from each of the
projects; derived data sets used in these analyses will be made
available at publication. An iHMP data coordination center
(http://hmpdacc.org) will work with the three teams to process
common data types in a uniform fashion to optimize data integra-
tion across the three studies. A summary of each project as
currently proposed and the assays to be executed is presented
in the following sections. These clinical studies are under IRB
oversight at their respective institutions. All study subjects have
been appropriately consented for broad data sharing in open ac-
cess databases except for protected subject data, which will be
deposited in the controlled access database, dbGaP.
iHMP Study: Integrative Multi-Omic Analysis of the
Vaginal and Related Microbiomes in Pregnancy,
Including Preterm Birth
The annual United States health care costs for newborns with
complications exceeds $26 billion (Behrman and Butler, 2007).
Worldwide, preterm birth is the leading cause of morbidity and
mortality among neonates. Recent decades have seen improved
survival of preterm neonates, but the incidence has not
decreased. Very preterm births (<32 weeks), which pose the
greatest health risks to the infant, are commonly caused by infec-
tion and inflammation in the uterine cavity (Goldenberg et al.,
2000). Intrauterine infection can cause premature rupture ofmem-
branes, preterm labor, and other complications. Evidence is accu-
mulating that the maternal microbiome undergoes significant
changes during pregnancy and plays a key role in fetal and infant
morbidity associated with health issues, including but not limited
to: gestational diabetes, low birth weight, necrotizing enteroco-
litis, and colic (Aagaard et al., 2012; de Weerth et al., 2013; Koren
et al., 2012; Prince et al., 2014; Romero et al., 2014a, 2014b).
Hence, the maternal microbiome likely plays a critical but largely
undefined role in the health of the pregnant woman and her fetus.
Project Description
The goal of the Multi-Omic Microbiome Study: Pregnancy Ini-
tiative (http://vmc.vcu.edu/momspi) is to study the dynamic
changes in the vaginal and related microbiomes and associated
host responses during normal pregnancy, in the development of
adverse outcomes of pregnancy, and in early infant microbiome
acquisition. It is hypothesized that various components of the mi-
crobiome are relevant to maternal, fetal, and neonatal health andCethat the microbiota contributes to preterm birth and stillbirth. To
explore these hypotheses, women will be enrolled early in preg-
nancy and followed longitudinally at multiple prenatal visits, at
admission to and discharge from labor and delivery, and at post-
partum visits. Enrollment will be skewed toward populations at
high risk for preterm birth. Microbiome compositions will be
measured by 16S rRNA gene surveys, whole metagenome
shotgun sequencing, and bacteriological cloning and sequencing.
Microbial and host gene expression profiles will be examined
by whole metatranscriptome sequencing, and cytokine and lipid
profiles will be explored. Protein-protein interactomic maps of
the microbiomes and the host will also be generated (Table 1).
Specifically, this project will:
1. Enroll up to 2,000 pregnant women and their neonates
from clinics associated with the VCU Health Center and
the Global Alliance to Prevent Prematurity and Stillbirth
(GAPPS). Women will be sampled at multiple body sites
(vagina, rectum, skin, nares, mouth, blood) longitudinally
throughout pregnancy, at labor and delivery, and at
follow-up visits. Neonates will be sampled at multiple
body sites (rectum, mouth, skin, nares, meconium, stool)
at birth and discharge visits. Placenta, cord blood, and
chorioamniotic membranes will be collected, and amniotic
fluid samples will be collected during cesarean deliveries.
2. Perform multi-omics analyses on maternal and neonatal
samples. All samples will be subjected to 16S rRNA
gene surveys and all vaginal and serum samples will
be subjected to lipidomic analysis. Selected samples will
be processed for whole metagenomic and whole meta-
transcriptomic sequence analysis, host transcriptome
profiling, cytokine profiling, bacteriological culture, and
protein-protein interaction analyses.
3. Integrate the data from thesemulti-omic studies into exist-
ing and local databases available to vaginal microbiome
investigators. The results will reveal associations between
the microbiome composition, microbial metabolic poten-
tial, gene expression profiles of the host and microbiota,
and the host cytokine and metabolome/lipidome expres-
sion profiles. Dynamic changes in the microbiomes and
in gene expression profiles will be monitored longitudinally
during and after pregnancy. Associations with preterm
birth, stillbirth, and other adverse outcomes of pregnancy
will be identified.
Overall, this research will reveal the impact of the microbiome
on the gene expression, cytokine, and metabolome/lipidome
profiles of pregnant women and their relationship to preterm
birth or other adverse outcomes of pregnancy. The long-term
objective of this study is to promote women’s health during preg-
nancy and prevent adverse outcomes.
Cohort Description
This study will longitudinally sample about 2,000 women, at least
15 years old, during and after their pregnancies. The neonates of
these women will also be sampled. The predicted racial/ethnic
composition of our cohort, based on the demographics of visi-
tors to the VCU and GAPPS collection sites, is highly diverse.
African Americans, who are at higher risk for preterm birth, repre-
sent about one-third of our anticipated cohort. Of the remainder,ll Host & Microbe 16, September 10, 2014 ª2014 The Authors 277
Table 1. Summary of Biospecimens, Primary Data, and Derived Properties to Be Collected for Each iHMP Cohort Study with Repositories for Primary Data
Source of
Property
Property Derived
from Primary Data
Primary Data from
Biospecimen
Biospecimen from Preterm
Birth Cohort
Biospecimen
from IBD Cohort
Biospecimen from
Prediabetic Cohort
Repository for
Primary Data
Microbiome microbial community
composition
16S rRNA gene survey cervicala, vaginala, rectal, buccal,
fetal membranes, placenta, amniotic
fluid from women; buccal, rectal,
stool, meconium, respiratory
secretions from neonate
stool anterior nares, stool SRA
microbial community
composition
whole metagenome
shotgun sequences
vaginala stool anterior nares, stool SRA
predictions of microbial
genes, metabolic pathways
whole metagenome
shotgun sequences
vaginala stool anterior nares, stool SRA
RNA transcript profiles whole metatranscriptome
shotgun sequences
vaginala stool anterior nares, stool SRA
microbiome
metaproteome profiles
LC-MS/MS peptide
profiles
– stool stool EBI PRIDE and/or
Peptide Atlas
viral community
composition
whole virome shotgun
sequences
– stool anterior nares, stool SRA
bacterial cultures bacterial isolates cervicala, vaginala, rectal, buccal,
stool from mothers or neonates
– – ATCC/BEI
bacterial whole genome
sequences
bacterial isolates cervicala, vaginala, rectal, buccal,
stool from mothers or neonates
– – SRA
bacterial whole genome
sequences
bacterial single-cell
sequences
– stool – SRA
single-cell bacterial RNA
transcript profiles
single-cell bacterial
transcript sequences
– stool – SRA
Host subject exome/whole
genome
subject genome
sequences
blood (futureb) from mothers
and neonates
blood blood dbGaP/SRA
RNA transcript profiles whole transcriptome
sequences
vaginala colon biopsy PBMCs dbGaP/SRA
and GEO
subject protein profiles LC-MS/MS peptide
profiles
– stool PBMCs, serum (future) EBI PRIDE and/or
Peptide Atlas
systemic inflammation
levels
cytokine profiles vaginala, buccal from mothers
or neonates
blood plasma Study DB
intestinal epithelial cell
cultures
intestinal epithelial cell
isolates
– colon biopsy – –
subject DNA methylation
profiles
reduced representation
bisulfite sequencing
(RRBS) profiles
– blood PBMC (future) SRA
(Continued on next page)
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Table 1. Continued
Source of
Property
Property Derived
from Primary Data
Primary Data from
Biospecimen
Biospecimen from Preterm
Birth Cohort
Biospecimen
from IBD Cohort
Biospecimen from
Prediabetic Cohort
Repository for
Primary Data
intestinal inflammation
levels
fecal calprotectin protein
concentrations
– stool – Study DB
serum antibody
composition
and levels
serology – blood – Study DB
subject contaminating
genome sequences
human sequence from
unfiltered total microbial
community sequences
vaginala stool stool dbGaP/SRA
subject profiles for
cohort
subject phenotypes,
clinical metadata,
medical panels
collected on each subject in
the study
collected on each
subject in the study
collected on each
subject in the study
dbGaP
Global (host and
microbiome)
protein-protein
interaction network
between host and
microbiome
yeast two-hybrid binary
protein complexes
vaginala – – EBI IntAct
pathway-level crosstalk
between host and gut
microbiome
intestinal epithelial cell
profiling response to
bacterial metabolites
– colon biopsy – dbGaP/SRA
and GEO
global metabolite
profiles
untargeted and targeted
LC-MS metabolomic profiles
– stool urine, plasma Metabolomics
Workbench
global lipid profiles untargeted and targeted
LC-MS metabolomic profiles
vaginala stool urine, serum Metabolomics
Workbench
aFrom mothers only
bSamples collected for possible future analysis
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Table 2. Glossary of Terms Used to Describe Primary Data in the Paper, in the Figures, and in Table 1.
Primary Data Type Definition
16S rRNA gene survey Sequence-based analysis of 16S ribosomal RNA gene in total DNA extracts; the data are used to develop microbial
community compositional profiles.
Whole metagenome
shotgun sequences
Sequence-based analysis of all genes in total DNA extracts; the data are used to develop microbial community
compositional, functional, and genomic profiles.
Whole metatranscriptome
shotgun sequences
Sequence-based analysis of RNA transcripts in a microbial community by converting RNA in total RNA extracts to
complementary DNA and sequencing the cDNA.
Whole virome shotgun
sequences
Sequence-based analysis of all virus genes and genomes used to develop viral community profiles. These sequence
data are derived from two approaches, either by first isolating viral-sized particles from a sample and then
sequencing this fraction, or by sequencing the DNA (or cDNA from RNA) extract and computationally determining
DNA and RNA viral sequences in the metagenome.
Bacterial isolates Isolation and cultivation of a specific bacterium in a mixed community through the use of selective media or
enrichment techniques to preferentially grow one bacterium of interest.
Single-cell genome
sequences
Physical separation or physical enrichment of a single microbial cell from a mixed population of cells. Sequence-
based analysis of the single cell’s genome is conducted using a DNA random priming method to first increase the
total DNA concentration in the cell and subsequently sequence this amplified DNA.
Single-cell RNA
sequences
Sequence-based analysis of RNA transcripts in a cell by converting RNA in total RNA extracts to complementary
DNA and sequencing the cDNA.
LC-MS/MS peptide
profiles
Analysis of individual peptides in a mixture of proteins by a combination of liquid chromatography and mass
spectroscopy after enzymatic digestion of the protein mixture. To derive the microbiome metaproteome, data from
the companionmetagenome is used along with KEGG and other protein databases to verify themicrobial proteins in
the total protein mixture. To derive the host proteins, a similar approach is used based on search against the human
genome.
Human subject whole
genome sequences
Analysis of the sequence of the host genome using high-throughput DNA sequencing.
Whole exome sequences Analysis of the protein coding regions of the host genome, which is generally done through sequence analysis.
Whole transcriptome
sequences
Sequence-based analysis of RNA transcripts in host tissue using polyA tail separation of eukaryotic transcripts from
a mixture of transcripts, converting the RNA to complementary DNA and sequencing the cDNA.
Cytokines Circulating immune system glycoproteins in blood, plasma, or other bodily fluids are measured through an ELISA
assay; data are used as a marker for systemic inflammation.
DNA methylation
profiles
Measurement of methylated regions of the host genome. This method uses a combination of restriction enzymes
and a reduced representation bisulfite sequencing (RRBS) method to enrich for regions of the genome with
cytosine-guanine pairs; these regions are then screened for methylated bases.
Fecal calprotectin
proteins
Fecal calprotectin is a protein found in stool, the concentration of which is measured through a standardized
immunoassay method and is used to evaluate levels of intestinal inflammation.
Serology Measurement of antibodies for specific pathogens or protein markers conducted with serum through an ELISA
assay.
Human subject
contaminating genome
sequences
Sequence from total nucleotide extracts from most microbially focused sample types yields a combination of host
and microbial sequence data. A computational filtering step, using human genome reference sequence, will
separate microbiome from human sequences.
Interactomes Analysis of protein-protein interactions betweenmembers of themicrobiota or between themicrobiota and the host.
Intestinal epithelial
cell profiles
Functional or sequence-based readouts of phenotypes for cell lines derived from primary epithelial cells from
individual hosts.
Metabolomes Measure of metabolomic profiles using untargeted and targeted LC-MS methods.
Lipidomes Measure of lipid profiles using 2D UPLC-ESI-MS/MS (ultra performance liquid chromatography combined with
electrospray ionization tandem mass spectroscopy) with an initial focus on AA (arachidonic acid) and eicosanoids.
Cell Host & Microbe
Perspectiveabout 37% will be Hispanic, 20% Caucasian, 5% Asian, and
4% Native American. Because high-risk populations attending
high-risk clinics will be sampled, it is anticipated that approxi-
mately 15%–20% of the study participants will deliver preterm.
Sampling
Samples will be collected from pregnant women at 3–5 antepar-
tum visits, at delivery, at discharge, and at subsequent follow-up
visits. Neonate samples will be collected at delivery and at
discharge. Placenta, cord blood, and amniotic fluid (C-section280 Cell Host & Microbe 16, September 10, 2014 ª2014 The Authorsonly) will be collected at delivery. Participants will complete
comprehensive electronic surveys that detail health history, back-
ground, habits, and diet. These data will be incorporated into a
secure database at VCU and a subset will be uploaded to dbGaP.
Vaginal, cervical, rectal, buccal, skin, and nares samples
will be collected with soft swabs. Cervical samples will be
collected during a speculum exam. Samples from the vagina
and rectum and the vaginal pH will be taken at each visit, except
discharge, and again at follow-up visits, either by a clinician or by
Figure 1. Integrative Multi-Omic Analysis of the Vaginal and Related Microbiomes in Pregnancy: Sample Collection, Assays, and Data
Generation Workflow
Samples from pregnant women and neonates will be collected at clinics associated with Virginia Commonwealth University and the Global Alliance to Prevent
Prematurity and Stillbirth (GAPPS). Health questionnaires will be administered and samples collected from multiple body sites over multiple visits throughout
pregnancy, at delivery, at discharge, and at follow-up visits. Neonates will be sampled at delivery, discharge, and follow-up visits. A multi-omic approach will
probe properties of the host and microbial communities to generate an integrative, longitudinal, and comprehensive data set of 16S rRNA gene surveys, mass
spectrometry-based lipidomic profiles, and cytokine assays. A subset of samples will be subjected to whole metagenome and metatranscriptome sequencin for
cultivation and isolation of bacterial strains for genome sequencing, and for generation of interactome maps.
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Perspectiveself-sampling. Buccal samples will be collected at each visit, and
skin (chest and antecubital fossa) and nares samples at each
visit except triage and delivery. Additional skin samples (chest
and dominant palm) will be collected at discharge. Blood will
be collected from participants early in pregnancy and again at
triage. Amniotic fluid will be collected with a sterile syringe,
and placenta and membrane samples will be collected with ster-
ile scissors. Cord blood will also be collected.
Buccal, rectal, meconium, stool, skin, and nares samples from
term and preterm neonates will be collected with soft swabs at
delivery and discharge. Tracheal aspirates will be collected
from neonates who are intubated. Over 100,000 samples will
be deposited into the RAMS Registry/Repository at VCU
(http://www.ramsregistry.vcu.edu) for future research.
Multi-Omic Assays
Samples will be subjected to a panel of technologies, including
16S rRNA gene surveys, whole metagenome and metatrans-
criptome shotgun sequencing, bacterial genome sequencing,
cytokine and lipid profiling, and generation of protein-protein
interaction networks of the microbiome and the host (Figure 1).
16S rRNA Gene Surveys for Microbiome Profiles: All Sample
Types. For 16S rRNA gene survey analysis, DNA will beCesequenced in barcoded pools using 2 3 250 bp PE technology
on an Illumina MiSeq sequencer in a standard pipeline that
generates more than 30,000 reads per sample. Reads will be
processed using the RDP Classifier (Wang et al., 2007) and as-
signed to species using STIRRUPS (Fettweis et al., 2012) or by
OTU-based methods to generate microbiome profiles.
Whole Metagenome Shotgun Sequencing and Whole
Metatranscriptome Sequencing: Vaginal Samples. To clarify the
contribution of the metabolic potential and gene expression pro-
files of the vaginal microbiome to preterm birth, case-matched
samples from 60 women who experience preterm birth and 60
women who experience normal term birth will be subjected to
in-depth whole metagenome shotgun sequencing and whole
metatranscriptome sequencing. Reads will be taxonomically
classified and quantified, andmetabolic reconstruction and anal-
ysis will be performed using the HUMAnN pipeline (Abubucker
et al., 2012), ASGARD (Alves and Buck, 2007), or similar tools.
Cytokine Profiles: Selected Vaginal and Buccal, Mother and In-
fant. The immune response will likely undergo dynamic changes
during pregnancy, and thesemay be particularly evident in cases
associated with adverse events. To monitor these changes, we
will analyze the profiles of a panel of cytokines, including somell Host & Microbe 16, September 10, 2014 ª2014 The Authors 281
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Perspectivethat were previously linked to preterm birth and/or inflammation
(IL-1a, IL-1b, IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 [p40], IL-12
[p70], IL-17, sCD40L, TNF-a, TNF-b, IFN-g) in vaginal (mother)
and buccal (mother and infant) samples. Representative vaginal
and buccal samples from the2,000 mothers and infants will be
analyzed. Analyses will be performed in a high-throughput
format using a multiplex magnetic bead-based human cytokine
ELISA assay.
Lipidomics: All Vaginal Samples. Bioactive lipids play an
important role in the maintenance of pregnancy and the induc-
tion of labor. These lipids are likely associated with the local mi-
crobiome and pregnancy outcomes. Thus, we plan to analyze
levels of more than 150 lipids (e.g., eicosanoids, sphingolipids,
and steroid hormones) in vaginal samples collected longitudi-
nally throughout pregnancy using methods previously described
(Wijesinghe et al., 2010, 2011). Assayswill employ liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) with a focus
on the metabolites that play a role in pregnancy and parturition.
Bacterial Genome Sequencing: Selected Samples from All
Sites. Many bacteria identified in 16S rRNA surveys of vaginal
samples, some of which are associated with women’s urogenital
health, have never been cultured or characterized. Several iso-
lates associated with preterm birth (Harwich et al., 2012) have
been cultured and characterized, and their pathogenic potential
is now being studied. Select isolates cultured from samples with
previously unidentified taxa associated with preterm risk will be
assayed for pathogenic potential and subjected to whole
genome sequence analysis. The assemblies will be deposited
into GenBank and the cultures at ATCC/BEI.
Interactomics: Protein-Protein Interaction Maps: Selected
Vaginal Samples. Microbes colonizing the vagina likely impact
vaginal health by secreting proteins that bind to or interact with
proteins of cocolonizers or the host. A pilot study will be per-
formed that will apply a novel yeast two-hybrid strategy that
invokes high-throughput in silico identification of interacting
partners using targeted next-generation sequencing of an ampli-
con including both bait and prey coding sequences from a spe-
cial hybrid construct following selection. If the pilot is successful,
the technology can be applied to interactions among complex
bacterial communities or between bacteria and the host.
iHMP Study: Characterizing the Gut Microbial
Ecosystem for Diagnosis and Therapy in IBD
Over the past decade, IBDs have emerged as one of the most
important human conditions linked to the gut microbiota
(Abraham and Cho, 2009; Danese and Fiocchi, 2011; Khor
et al., 2011; Xavier and Podolsky, 2007). IBD comprises both
Crohn’s disease (CD) and ulcerative colitis (UC), which together
affect nearly 1.5 million Americans (Loftus, 2004). Studies of
environmental (Baumgart and Sandborn, 2012; Molodecky
et al., 2011; Orda´s et al., 2012; Renz et al., 2011) and microbial
(Packey and Sartor, 2009; Sokol et al., 2008) associations with
IBD have resulted in neither simple diagnostic markers nor
targetable points of intervention. Instead, IBD has been repeat-
edly linked to the overall ecology of the human gut microbial
ecosystem, including community diversity (Frank et al., 2007;
Manichanh et al., 2006; Ott et al., 2004), a range of microbial
over- and underabundances (Joossens et al., 2011; Scanlan
et al., 2006; Sokol et al., 2009;Willing et al., 2009), and the deple-282 Cell Host & Microbe 16, September 10, 2014 ª2014 The Authorstion and enrichment of microbial metabolic activities (Erickson
et al., 2012; Meyer et al., 2012; Morgan et al., 2012). To date,
however, no one aspect of the gut microbiome has yielded
data that identify causal biomolecular mechanisms in IBD or pro-
vide a translationally actionable target for IBD.
Project Description
An IBD multi-omic database, the IBDMDB (http://ibdmdb.org),
comprising an integrated data resource, will be developed to
enable the gut microbial ecosystem as a target for diagnosis,
therapy, and mechanistic understanding of IBD. This study will
leverage well-phenotyped patient cohorts in both pediatric and
adult populations to provide longitudinal profiling of the biolog-
ical properties of the human gut microbiome in IBD. To further
characterize the microbiota’s mechanisms of host interaction,
profiles of host genetic and functional properties from a subset
of longitudinal time points will also be collected. In addition to
data beingmade rapidly accessible to the community by building
on this research group’s current computational infrastructure for
multi-omic data processing and distribution, this study will vali-
date and distribute its sample collection and bioinformatic proto-
cols, including platforms for single-cell- and host-cell-focused
multi-omic assays.
The biological questions of interest to be addressed by the
multi-omic data generated by this project include (1) identifying
the molecular mechanisms by which the intestinal microbiome
may trigger disease activity in patients with IBD, (2) determining
if microbial composition predicts subsequent risk of flares in
disease activity, and (3) testing whether successful response to
therapy can be predicted from the stool microbiota. These hy-
potheses are testable by the dense longitudinal multi-omic
surveys of the IBD patients and controls in this study design.
Specifically, this project will:
1. Create an integrated data repository, the IBDMDB, for
standardized community access tomulti-omic data, build-
ing on existing resources and supporting rapid future
algorithm development. This will begin with a pilot data
set of existing multi-omic data from two cohorts, including
cross-sectional and longitudinal 16S, metagenomic, me-
tabolomic, and proteomic profiles.
2. Implement and validate standardized stool and biopsy
sample collection methods among three established IBD
patient cohorts.
3. Recruit well-characterized subjects within these three co-
horts targeting, respectively, new-onsetpediatric subjects,
new-onset adult subjects, and established Crohn’s dis-
ease and ulcerative colitis, in addition to non-IBD controls.
4. Longitudinally collect stool samples and, for a subset of
collection points, rectal and colon biopsies from which mi-
crobial 16S surveys, metagenomic and metatranscriptomic
sequences, viromes, metabolites, and proteins will be sur-
veyed. A subset of stool andbiopsy sampleswill additionally
provide 16S and metagenomic and metatranscriptomic
populationanalyses throughsingle-cell techniques (Table1).
5. Acquire host information, including rich clinical and
phenotypic metadata for all collection points and, for a
subset, host genetics, gene expression data, DNAmethyl-
ation profiles, serology, and primary intestinal epithelial
cells for profiling response to microbial products.
Cell Host & Microbe
PerspectiveCohort Description
The study will collect stool samples, biopsies, and blood sam-
ples from three clinical cohorts. The primary sample will be serial
stools every 2 weeks for 1 year, which will be analyzed using 16S
rRNA gene surveys, whole metagenome and metatranscriptome
shotgun sequencing, metabolomics, whole virome shotgun
sequencing, proteomics, and a fecal calprotectin assay. Intesti-
nal biopsies will also be collected at a standardized rectal loca-
tion for all subjects, plus at the site of active inflammation for IBD
patients, at time zero and as clinically indicated over the
following year (approximately one additional time point per sub-
ject). 16S surveys will be carried out on these biopsies, in addi-
tion to host whole transcriptome sequencing and host cell
profiling by culture. A subset of biopsies and stools will be addi-
tionally assessed by single-cell 16S and whole metagenome and
metatranscriptome shotgun sequencing. Finally, blood samples
will be drawn at recruitment and 6 month intervals for host ge-
netics, serology, and epigenetics by reduced representation
bisulfite sequencing (RRBS).
This study includes three IBD cohorts providing these samples
and metadata, coupled with two additional cohorts from which
early ‘‘proof-of-principle’’ data are already available. The sam-
ples described above will be collected from (1) PRISM (the
Prospective Registry in IBD Study at MGH), recruiting fromMas-
sachusetts General Hospital (Ananthakrishnan et al., 2014; Mor-
gan et al., 2012); (2) the MLI (Mucosal Luminal Interface) cohort
recruiting from Cedars-Sinai Medical Center (McHardy et al.,
2013; Tong et al., 2013); and (3) a pediatric IBD cohort recruiting
from Emory University and Cincinnati Children’s Hospital (Ge-
vers et al., 2014; Walters et al., 2014). Each cohort will provide
30 subjects (12 CD, 12 UC, and 6 non-IBD controls), with MGH
focusing on new-onset adult patients, CSMC on adult patients
with established disease, and Emory/Cincinnati on new-onset
pediatric patients. Together, these cohorts have previously
enrolled a total of over 3,600 subjects and collected more than
1,500 samples. A smaller, existing multi-omic data set is
included in this study as a proof-of-principle, derived from two
Swedish cohorts, the Swedish Twin and Swedish Longitudinal
studies of IBD (Dicksved et al., 2008; Erickson et al., 2012;Willing
et al., 2010). These include up to 40 twin pairs and 119 individ-
uals providing up to ten time points, respectively, and represent
one of the only existing multi-omic data sets in IBD around which
the computational infrastructure will be organized and proto-
typed.
Sampling
This study has already established a convenient method for self-
collected fecal samples compatible with all of the multi-omic as-
says, enabling longitudinal profiling in smaller collection tubes
tolerant of over 24 hr at ambient temperature (Franzosa et al.,
2014). Two tubes are provided per subject, one dry (for prote-
omics and calprotectin) and the other containing an ethanol fixa-
tive (for all other assays). Validation studies indicate that there is
close agreement between freshly frozen fecal sample assays
and samples in preservative. Each fecal collection tube cap in-
cludes a spoon for easier collection and can be shipped under
ambient conditions, and clear instructions are provided to the
subjects (publicly available at http://ibdmdb.org/protocols).
Each sample is shipped by subjects in a self-addressed, prepaid
FedEx box for same-day delivery, with aliquots distributed inCesubsequent batches for off-site assays. Samples are accompa-
nied by short metadata questionnaires, and clinical data at first
visit includes demographics, disease characterization (including
medication history), short- and long-term food frequency ques-
tionnaires, and an environmental factors questionnaire.
Multi-Omic Assays
Microbial Community Composition, Functional Potential and Ac-
tivity: All Samples. The first tier ofmulti-omic data in IBD (Figure 2)
will include 16S rRNA surveys, whole metagenomic shotgun
sequencing, and whole metatranscriptome shotgun sequencing
from stool samples (all assays) and biopsies (16S only).
Improving our understanding of complex human-associated mi-
crobial communities will require at a minimum the aspects of mi-
crobial community structure, its functional potential, and realized
gene expression activity. This dictates the inclusion of 16S rRNA
gene-based, whole metagenome DNA shotgun-based, and
community mRNA-based sequencing (Gevers et al., 2012).
This study will also survey the nonbacterial members of the gut
microbiota, including archaeal, viral, and eukaryotic compo-
nents. This study includes a viral enrichment and sequencing
protocol for each stool sample.
Metabolomic and Protein Profiles: Stool Samples. This study
will measure metabolomic and protein profiles of stool samples
from participants in the project cohorts using a combination of
mass spectrometry (MS) methods. Four LC-MS/MS approaches
will measure complementary metabolite classes using sensitive,
high-resolution mass spectrometers enabling nontargeted mea-
surements of known metabolites (several hundred in total) and
unidentified metabolites in the same run. For each stool sample,
metabolites will be identified using reference data generated
from an in-house Broad Institute library of > 500 compounds,
and novel metabolites will be annotated using a database of >
8,000 metabolites and confirmed using references when
possible.
Protein profiles will be measured by two-dimensional nano
liquid chromatography (2D-LC) and tandem mass spectrometry
(MS/MS) (Cantarel et al., 2011; Presley et al., 2012), with proteins
identified by searching custom databases consisting of the hu-
man genome, matched metagenomes from the same samples,
and a defined set of reference genomes, including many that
are in the HMP reference genome database. Based on prelimi-
nary results, it is anticipated that > 3,000 proteins will be identi-
fied per sample and that approximately half of the proteins will be
human proteins based on a pretested method for preparation of
the protein extracts. The combination of human and microbial
protein data will provide a window into the types of host-microbe
interactions that occur in the gut and how these functions are
correlated to IBD.
Host Biomolecular Activities in the Gut: Colon Biopsy Samples
and Cultured Host Cells. To begin linking gut microbial commu-
nity biology to that of the host, this study will assess changes in
host biomolecular activities in the gut as part of multi-omic
profiling. Specifically, host gene expression will be assayed by
RNA-seq from colon biopsies (from a standardized rectal loca-
tion in all subjects and from the active site of IBD in patients)
and the DNA methylation state of the host genome in circulating
blood by RRBS. This will allow the discovery of links between
epigenetic content and disease states relating to microbial com-
munities. Finally, to detail pathway-level crosstalk between gutll Host & Microbe 16, September 10, 2014 ª2014 The Authors 283
Figure 2. Characterizing the Gut Microbial Ecosystem for Diagnosis and Therapy in Inflammatory Bowel Disease: Sample Collection, Assay,
and Data Generation Workflow
Samples from Crohn’s disease patients, ulcerative colitis patients, and non-IBD controls are collected at Massachusetts General Hospital (adult new onset),
Emory University (pediatric new onset), Cincinnati Children’s Hospital (pediatric new onset), and Cedars-Sinai Medical Center (adult established). From each
patient, three different types of samples are collected: longitudinal stool samples, periodic biopsies, and regularly scheduled blood samples. Biopsies are
collected as clinically indicated, blood during clinical visits, and stool samples are self-collected by participants at home and shipped directly to a centralized
handling and aliquotting pipeline. Multi-omic data generation (primarily, but not entirely, nucleotide sequence- and mass spectroscopy-based) provides mi-
crobial, host, and mixed profiles including 16S rRNA gene surveys, whole metagenome and metatranscriptome shotgun sequences, metabolite and protein
profiles, single-cell assays, whole virome shotgun sequences, and serological profiles. Each sample is further accompanied by clinical (bloods/biopsies) or self-
reported environmental and dietary (stools) metadata.
Cell Host & Microbe
Perspectivemicrobes and the intestinal epithelium, host cells isolated from
primary biopsy samples will be cultured and perturbed in vitro
(Gallo and Hooper, 2012; Maynard et al., 2012; Stappenbeck
et al., 1998) to determine the relative contribution of metabolites
and host epithelial cells in this crosstalk.
iHMP Study: Microbiome and Host Changes during
Respiratory and Other Stress Conditions in Individuals
at Risk for T2D
Type 2 diabetesmellitus (T2D) is a significant health problem fac-
ing our nation. Close to 20 million individuals in the United States284 Cell Host & Microbe 16, September 10, 2014 ª2014 The Authorshave T2D, costing hundreds of billions of dollars annually, and
the incidence is projected to double by 2050 (American Diabetes
Association, 2008). Differences in the gut microbiome have been
noted between diabetics and healthy individuals (Qin et al.,
2012), and direct alteration of the microbiome in mice has
been shown to lower glucose levels (Turnbaugh et al., 2006).
The hypotheses to be tested in this study include the following:
(1) environmental stress causes dynamic changes in specific
biological pathways in the human body, and these changes
lead to alteration of the humanmicrobiome and themetabolome,
including glucose; (2) some of the changes may affect the
Cell Host & Microbe
Perspectiveepigenome, leading to molecular and biological alterations that
extend well beyond the time of the stress period; and (3) different
physiological stresses, such as respiratory viral infections and
diet changes, may have common effects in both the host andmi-
crobiome.
Project Description
To better understand the biological changes that occur during
the onset and progression of T2D, this study (http://med.
stanford.edu/ipop/) will perform a detailed analysis of the biolog-
ical processes that occur in the human microbiome and host by
longitudinal profiling of patients at risk for T2D during healthy and
stress periods. Multiple sample types will be collected from the
study participants every 2–3months during their healthy periods,
with more frequent sampling during periods of respiratory illness
and other environmental stress. Multiple microbiome biological
properties will be analyzed. Changes in host functional profiles
will also be revealed.
This study is designed to develop a detailed understanding of
the physiological changes that occur in the microbiome and host
during viral infection and during changes in glucose levels and in-
sulin resistance. This longitudinal study is expected to reveal
changes in the microbiome and host at an unprecedented level
and frequency and to identify the molecules and pathways that
change during viral infections and diabetes onset and progres-
sion. Specifically, this project will:
1. Establish a cohort of approximately 60 consented individ-
uals at risk for T2D. Dense sampling will occur during res-
piratory infection and other stress states, with less frequent
sampling every 2–3 months during healthy periods,
2. Perform multi-omic analysis of longitudinal microbiome
and host samples (Table 1). Microbiome genomic,
transcriptome, and proteome content will be determined
in fecal and nasal samples and in peripheral blood mono-
cyte cell (PBMC) samples for viral and endogenous micro-
biome populations. Host genomic, transcriptomic, and
proteomic data will be concurrently analyzed in blood
components (PBMCs for genome and transcriptome;
plasma for proteome). Combined microbiome and host
metabolites will be analyzed in serum and urine. Antivir-
ome antibodies will also be analyzed.
3. Analyze and integrate omic information from the micro-
biome and host. The different omics information (genome,
transcriptome, and proteome) from nasal and fecal sam-
ples will be analyzed individually and in a combined
fashion to determine the dynamic pathways that change
during viral infection. In addition this study will correlate
microbiome omic temporal profiles with those of the
host to obtain an unprecedented view of the global micro-
biome-host changes that occur during viral infections.
Cohort Description
This study will execute a 3 year study in 60 males and females at
high risk for T2D. Those individuals with either impaired fasting
glucose (fasting plasma glucose > 100 mg/dl) or impaired
glucose tolerance (2 hr glucose > 140mg/dl in oral glucose toler-
ance test) will be enrolled. In order to further increase the number
of study participants with chances of conversion to diabetes, but
to maintain some degree of homogeneity in study subjects, theCestudy will include only those volunteers with body mass index
25–40 kg/m2 and age 35–65 years. Given estimates of 11% con-
version to frank diabetes per year (Ratner and Diabetes Preven-
tion Program Research, 2006), the study anticipates up to ten
cases of diabetes to occur over the 3 year study period. All par-
ticipants will receive genetic counseling prior to enrollment.
Sample and Data Collection
Qualified and consented participants will proceed to baseline
testing, which includes a blood draw for molecular omics anal-
ysis, as well as measurement of fasting lipid panel markers
HbA1c and hsCRP. Subjects will return every 3 months for blood
draws and microbiome samples and will complete online sur-
veys that are automatically sent to them to document changes
in medications, activity, body weight, blood pressure, diet, men-
strual cycle, stresses, etc. Subjects will undergo frequent sam-
pling during periods of environmental or medical stress. In this
study, stresses are defined as medical illness, physical injury/
pain, major or minor operation, major life changes (birth, death,
divorce, marriage, and change of home or job). The study will
reinforce different collection schemes depending on types of
stress events; for example, in cases of viral infection, the study
will collect samples on days 1, 2, 4, 7, 21, and 35 after the onset
of infection symptoms.
For each visit, either quarterly healthy visit or during stress pe-
riods, the study will collect peripheral blood to prepare PBMCs,
plasma and serum, as well as urine and microbiome samples
(nasal, fecal, skin, and tongue) using standard HMP protocols.
Multi-Omic Assays
To better understand the relationship between healthy and
stressed states in this cohort, the study will be analyzing a suite
of omic properties from both the host and microbiome. These
include whole metagenome shotgun and metatranscriptome
sequencing, host whole genome/transcriptome sequencing,
cytokine and autoantibody profiles, metabolomics profiles, and
standard clinical tests (Figure 3).
Whole Metagenome Shotgun and Metatranscriptome
Sequencing: Stool and Nasal Samples. To follow the diversity
of the microbiome in prediabetics and how it changes during
stress periods, both 16S and whole metagenome shotgun
sequencing of nucleic acids isolated from nasal and stool sam-
ples will be performed. Previously established HMP methods
for alignment of whole metagenomic shotgun sequences to
reference genomes will be used (Human Microbiome Project
Consortium, 2012a, 2012b; Martin et al., 2012) for computation
of taxonomic representation and breadth and depth of coverage,
for variant calling in metagenomic data (Schloissnig et al., 2013),
for pathway analysis (Abubucker et al., 2012), and for virome
analysis (Wylie et al., 2012a, 2012b).
To follow microbiome activity, microbial gene expression will
be analyzed. Bacterial RNA will be isolated and enriched for
mRNA using procedures that remove > 95% of 16S and 23S
rRNAs (Maurice et al., 2013; Turnbaugh et al., 2009). The result-
ing RNA is converted into cDNA using random priming and
sequenced using the Illumina platform. Analysis of gene expres-
sion for each genewill follow previously published computational
pipelines and algorithms (Maurice et al., 2013; Turnbaugh et al.,
2009).
Host Whole Genome/Transcriptome Sequencing: PBMCs. To
better understand how each subject responds to dynamicll Host & Microbe 16, September 10, 2014 ª2014 The Authors 285
Figure 3. Microbiome and Host Changes during Respiratory and Other Stress Conditions in Individuals at Risk for Type 2 Diabetes: Sample
Collection, Assay, and Data Generation Workflow
All samples are collected at the Stanford Clinical & Translational Research Unit. From each patient in every visit, blood sample andmicrobiome sample (including
nasal swabs and stool and urine samples) are collected. Multi-omic data generation (primarily, but not entirely, nucleotide sequence- and mass spectroscopy-
based) will provide profiles of microbial phylogenetic composition, metagenomes, metatranscriptomes, and metaproteomes; host protein profiles, cytokines,
and autoantibodies; and global metabolome profiles. Each sample is further accompanied by clinical (blood) or self-reported stress level, environmental, and
dietary (stool and urine) metadata.
Cell Host & Microbe
Perspectivechanges as well as to facilitate mapping for downstream tran-
scriptome and proteome analyses, participants will have their
genome sequenced (from PBMCs) using Illumina technology.
Single nucleotide variants, short insertions and deletions
(<100 bp Indels), and structural variants will be scored using
the HugeSeq pipeline (Lam et al., 2012). For each PBMC sample,
the transcriptome will be analyzed using RNA-seq, involving the
random primed synthesis of cDNA from RNA depleted of rRNA.
The readswill bemapped, and gene expression, isoform expres-
sion, allele expression, and RNA editing will be mapped using a
previously published pipeline (Chen et al., 2012).286 Cell Host & Microbe 16, September 10, 2014 ª2014 The AuthorsMicrobiome and Host Protein Expression Profiles Using LC-
MS/MS: Fecal and PBMC Samples. Most studies analyze RNA
expression; however, protein levels often do not correlate well
with RNA expression levels (Maier et al., 2009). Therefore, micro-
bial and host protein expression will also be analyzed from fecal
samples and host PBMC cells, respectively. Proteins will be ex-
tracted, trypsin digested, and analyzed by 2D-LC and MS/MS
(Chen et al., 2012). MS/MS spectra will be searched using the
Sequest algorithm against human and microbiome protein data-
bases and a specialized database of each individual based on
the microbiome metagenome and host genome sequence.
Cell Host & Microbe
PerspectiveProtein false discovery rates of 1%and only proteins with at least
two peptides will be used. Relative protein levels using TMT
isobaric tags and a reference sample prepared from multiple in-
dividuals or time points will be quantified (Chen et al., 2012). The
dynamic changes in protein levels will be scored during healthy
and stress periods.
Cytokines and Autoantibody Profiles: Serum. Since inflamma-
tion and immune responses have been implicated in T2D (Esser
et al., 2014; Shu et al., 2012), and viral infections dramatically
affected the immune response, the levels of 50 diverse cytokines
(e.g., inflammatory proteins such as TNF-a, IFN-a, CRP, and in-
sulin peptides) in host serum will be followed using throughput
ELISA assays (Chen et al., 2012). Autoantibodies and antiviral
antibodies will be profiled from selected sera using the Invitrogen
ProtoArray Protein Microarray v5.0, which contains 9,483 unique
human proteins (Hudson et al., 2007), and other comprehensive
human and virome arrays.
Metabolomes: Urine and Plasma. Since diabetes is a meta-
bolic disease (Akash et al., 2013), it is of particular importance
to profile as many metabolites as possible (Friedrich, 2012),
many of which are likely synthesized or influenced by the micro-
biome. To gain insight into the breadth of metabolic changes that
occur, untargeted metabolomics profiling of urine and plasma
samples will be performed using an optimized LC-MS procedure
(liquid chromatography coupled to mass spectrometry). Two
complementary separation methods will be combined and run
in ESI (electrospray ionization) positive and negative modes to
maximize the metabolome coverage from polar to nonpolar me-
tabolites: HILIC (hydrophilic interaction liquid chromatography)
and RPLC (reverse-phase liquid chromatography). The MS
data will be acquired using high-sensitivity, high-resolution
mass spectrometers. The optimized analytical procedure will
monitor 18,000 and 14,000 metabolic features, characterized
by a unique retention time and exact mass, for each urine and
plasma sample, respectively. Metabolites will then be annotated
using public databases of > 40,000 metabolites, and their iden-
tity will be confirmed with authentic standards when possible.
Standard Clinical Tests: Plasma and Serum. Standard clinical
tests will be performed to follow typical plasma and serum
markers.Wewill quantify lipids, lipoproteins, hsCRP, hemaglobi-
nA1c, insulin, and glucose. The degree of hyperglycemia and in-
sulinemia and insulin resistance of subjects will be measured.
When patients are ill, standard nasal swabs will be used to iden-
tify the pathogen, which will complement the microbiome ana-
lyses. The clinical data may be redundant with the omics profiles
presented above but will both serve as useful controls and
ensure that no key metabolite is missed. In order to document
behavior changes of patients, emotional and psychological
stress will be quantified using the Perceived Stress Scale instru-
ment, which measures an individual’s perception of stress
(Cohen et al., 1983). Physical activity will be scored using the In-
ternational Physical Activity Questionnaire (Hallal and Victora,
2004), and food intake will be recorded for the last 24 hr before
each visit.
Conclusion
These three examples of microbiome-associated human condi-
tions will provide innovative, freely available, multi-omic data of
properties analyzed in both the microbiome and host with whichCeto explore the behavior of the human microbiome over the
course of complex conditions using preterm birth, onset of
IBD, and onset of T2D as dynamic model systems. In addition,
theywill help lay the foundation for shared protocols and analysis
methods for highly detailed studies of the microbiome’s basic
biology and translational potential. Data produced by the iHMP
Consortium will be routinely released, and ongoing feedback is
encouraged on how best to leverage these resources. For those
interested in participating in the iHMP Consortium or learning
more about the iHMP data sets or tools, please either contact
the corresponding author or send an inquiry via the iHMP portal
(http://hmp2.org).
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